权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Microbicide Loaded Nanocarriers for Topical Delivery in HIV/AIDS Prevention

负载杀菌剂的纳米载体用于局部递送以预防艾滋病毒/艾滋病

基本信息

批准号：
7897758
负责人：
Bi-Botti Celestin Youan
金额：
$ 17.19万
依托单位：
UNIVERSITY OF MISSOURI KANSAS CITY
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-07-22 至 2012-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7897758
关键词：
AIDS prevention AIDS/HIV problem Acquired Immunodeficiency Syndrome Adherence Africa Anti-Retroviral Agents Biological Assay Caliber Cells Cervical Charge Chitosan Cream Dendritic Cells Development Disease Dosage Forms Dose Drug Carriers Drug Controls Drug Formulations Encapsulated Ensure Eudragit Gel Goals HIV HIV Infections HIV vaccine HIV-1 Heating Heparin Human Immune In Vitro Infection Knowledge Lactobacillus Lead Ligands Lipids Local Microbicides Malignant Neoplasms Methods Modeling Morphology Mucous Membrane Nucleotides Outcome Particle Size Penetration Persons Pharmaceutical Preparations Physical Chemistry Polyesters Polymers Prevention Prevention strategy Preventive Regimen Research Personnel Reverse Transcriptase Inhibitors Risk Safety Scientist Seminal Plasma Seminal fluid Services Sexually Transmitted Diseases Site Solid Stimulus Structure Surface System Tenofovir Testing Therapeutic Toxic effect Vagina Virus Virus Diseases Woman Work base biomaterial compatibility compliance behavior condoms controlled release cost dosage drug efficacy efficacy testing falls fluorescence imaging human disease improved innovation lymph nodes meetings methylmethacrylate-methacrylic acid copolymer microbicide monocyte nanocarrier nanoformulation nanosized novel particle polyarginine prevent public health relevance safety testing skills trafficking transmission process uptake vaccine candidate

项目摘要

DESCRIPTION (provided by applicant): Every day over 6800 new infections take place and 5700 persons die from Human immunodeficiency virus infections (HIV/AIDS) worldwide, mostly because of inadequate access to HIV prevention and treatment services. Women who acquired HIV-1 through vaginal intercourse represent <60% of new infections in Africa. Still today, there is no known cure for the condition. Thus, there is a critical and urgent need for effective control methods and strategies to prevent the continuous spread of HIV/AIDS and break the cycle of the new HIV infections. Although an HIV vaccine would be the most suitable prevention strategy, an effective or even partially effective vaccine candidate has yet to be identified. Thus the development of a topical microbicide which can be used, unlike condoms, by women without the knowledge of their partner would provide a major benefit for slowing the global spread of HIV-1. Ideally a successful microbicide delivery system will have to (i) protect mucosal surfaces at risk of HIV-1 transmission, (ii) prevent the dissemination of infected cells from the local mucosa to the regional lymph nodes and, (iii) provide a controlled release of the microbicide to ensure long lasting protecting effect, (iv) be stimuli-sensitive to maximize the drug efficacy and provide required preventive dose on demand. The currently use of gel-based systems do not meet all these requirements. Thus nanosized drug carriers or drug loaded nanocarriers (NC) appear as promising alternative. Our long term goal is to identify novel multifunctional nanocarriers for controlled delivery of the microbicide either for prevention or treatment of HIV/AIDS. The objective of this proposal is to use nanocarrier for the controlled delivery of a model topical microbicide (Tenofovir). We have recently prepared several bioactive agents loaded chitosan and polyester nanocarrier with particle diameter ranging from <100 nm to <1000 nm. The central hypothesis is that a topical microbicide loaded nanocarrier is safer and more effective than the native drug in HIV/AIDS prevention. We will test this hypothesis with the following three specific aims. Specific aim#1: To develop a microbicide loaded bioadhesive nanocarrier for topical delivery in order to enhance the drug local duration of action. Specific aim#2: To develop a microbicide loaded pH sensitive nanocarrier for topical delivery in order to take advantage of the pH increase during intercourse to trigger effective drug dose release for an enhanced action. Specific aim#3: To develop a microbicide loaded functionalized nanocarrier with cell penetrating ligands in order to prevent the dissemination of the virus from the local mucosa to the regional lymph nodes. In each aim in order to identify optimal NC, we will thoroughly characterize the developed NC physico-chemically, assess their safety by MTT and Lactobacillus toxicity assay, test their efficacy in vitro (with seminal plasma, human PBMC-based and cervical explants assays) and elucidate their intracellular trafficking mechanism. It is anticipated that this innovative approach will lead to the identification of NC as a safer and more effective alternative to current microbicide delivery systems in HIV/AIDS prevention. PUBLIC HEALTH RELEVANCE: Our long-term goal is to thoroughly identify and characterize a novel microbicide nanocarrier system to improve the safety and efficacy in the prevention of HIV/AIDS transmission process. Specifically, the objective of this application is to develop tenofovir (a model microbicide) loaded nanocarriers that may be made of either bioadhesive (for longer topical duration of action), pH-sensitive (for a triggered release by semen either pH) or functionalized solid lipid matrix (for deeper penetration across the potential path of HIV virus) for prevent the dissemination of the virus. It is anticipated that knowledge gained from this work may be applicable to other microbicides and to other sexually transmitted diseases or human diseases.

描述（由申请人提供）：全世界每天有6800多例新感染，5700人死于人类免疫缺陷病毒感染（艾滋病毒/艾滋病），主要原因是无法获得艾滋病毒预防和治疗服务。在非洲，通过阴道性交感染艾滋病毒-1的妇女占新感染人数的60%以下。直到今天，这种病还没有已知的治疗方法。因此，迫切需要有效的控制方法和战略，以防止艾滋病毒/艾滋病的持续蔓延，打破新的艾滋病毒感染的循环。尽管艾滋病毒疫苗将是最合适的预防策略，但尚未确定一种有效甚至部分有效的候选疫苗。因此，开发一种局部使用的杀微生物剂，不像避孕套，可以让女性在伴侣不知情的情况下使用，这将为减缓艾滋病毒-1的全球传播带来重大好处。理想情况下，一个成功的杀微生物剂输送系统必须(i)保护有HIV-1传播风险的粘膜表面，（ii）防止感染细胞从局部粘膜扩散到局部淋巴结，（iii）提供杀微生物剂的可控释放，以确保持久的保护效果，（iv）对刺激敏感，以最大限度地提高药物功效，并根据需要提供所需的预防剂量。目前使用的凝胶基系统不能满足所有这些要求。因此，纳米药物载体或载药纳米载体（NC）是一种很有前途的选择。我们的长期目标是确定新的多功能纳米载体，用于控制杀微生物剂的递送，以预防或治疗艾滋病毒/艾滋病。本提案的目的是使用纳米载体来控制一种模型局部杀微生物剂（替诺福韦）的递送。近年来，我们制备了几种以壳聚糖和聚酯为载体的生物活性制剂，其粒径范围从<100 nm到<1000 nm。该研究的核心假设是，在预防艾滋病方面，负载纳米载体的局部杀微生物剂比天然药物更安全、更有效。我们将用以下三个具体目标来检验这一假设。具体目标#1：开发一种装载杀微生物剂的生物黏附纳米载体，用于局部递送，以提高药物的局部作用时间。具体目标2：开发一种载有杀微生物剂的pH敏感纳米载体，用于局部递送，以便利用性交过程中pH值的增加来触发有效的药物剂量释放，以增强作用。具体目标#3：开发具有细胞穿透配体的杀菌剂负载功能化纳米载体，以防止病毒从局部粘膜传播到区域淋巴结。在每个目标中，为了确定最佳NC，我们将彻底表征所开发的NC的物理化学特性，通过MTT和乳酸菌毒性试验评估其安全性，在体外（用精浆，人pbmc和宫颈外植体试验）测试其功效，并阐明其细胞内运输机制。预计这一创新方法将导致NC作为一种更安全、更有效的替代现有的杀微生物剂递送系统，用于预防艾滋病毒/艾滋病。公共卫生相关性：我们的长期目标是彻底鉴定和表征一种新型杀微生物剂纳米载体系统，以提高预防艾滋病毒/艾滋病传播过程的安全性和有效性。具体来说，本申请的目的是开发替诺福韦（一种模型杀微生物剂）负载的纳米载体，可以由生物粘合剂（更长的局部作用时间）、pH敏感（由精液触发的pH值释放）或功能化固体脂质基质（更深地穿透HIV病毒的潜在途径）制成，以防止病毒的传播。预计从这项工作中获得的知识可能适用于其他杀微生物剂和其他性传播疾病或人类疾病。